Cagrilintide-RUO 5mg

Cagrilintide 5mg is a synthetic, long-acting analog of human amylin, modified for enhanced stability, prolonged half-life, and dual agonism at amylin receptors (AMYRs) and calcitonin receptors (CTRs). This investigational peptide features an N-terminal acylation with a C20 fatty diacid linked via a γ-glutamyl spacer for reversible albumin binding, resulting in extended pharmacokinetics (reported half-life approximately 180–200 hours in relevant models). The backbone incorporates key substitutions including N14E and V17R for helix stabilization and solubility, proline residues (e.g., at positions 25, 28, 29) to minimize β-sheet formation and fibrillation risk, and a C-terminal proline amidation to optimize receptor interactions.
Supplied as high-purity lyophilized powder (>98% purity, verified by HPLC and mass spectrometry), with a molecular formula of C₁₉₄H₃₁₂N₅₄O₅₉S₂ and approximate molecular weight of 4409 Da. The sequence is: {Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH₂ (disulfide bridge between Cys³-Cys⁸).
Cagrilintide is intended exclusively for in vitro research and scientific experimentation. It is commonly utilized in preclinical laboratory models to investigate satiety signaling pathways, appetite regulation mechanisms, gastric emptying dynamics, energy homeostasis, receptor binding and activation at AMYRs/CTRs, metabolic signaling cascades, and related processes in cellular assays, tissue models, or animal systems exploring obesity, metabolic disorders, and neuroendocrine regulation.